title: Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab.
abstract: Progressive multifocal leukoencephalopathy (PML) is a complication of natalizumab treatment. In order to identify natalizumab-treated patients at risk of developing PML, we assayed for anti-JC virus (JCV) antibody levels in cerebrospinal fluid (CSF). Serial CSF antibody levels were obtained, with 4 patients showing increases in anti-JCV levels indicating possibly viral activation. In patients with both CSF and serum antibody levels, a comparison showed only a moderate Spearman Rank Correlation Coefficient of 0.38. Our data suggests that serum anti-JCV antibody testing alone may not suffice in identifying at-risk patients because of the lack of uniform correlation with CSF titers.
authors.affiliation: Tisch Multiple Sclerosis Research Center of New York, 521 West 57th Street 4th Fl., New York, NY 10019, USA.
authors.forename: Jerry
authors.initials: J
authors.lastname: Lin
authors.forename: Peggy
authors.initials: P
authors.lastname: Bettin
authors.forename: John K
authors.initials: JK
authors.lastname: Lee
authors.forename: Joseph K
authors.initials: JK
authors.lastname: Ho
authors.forename: Saud A
authors.initials: SA
authors.lastname: Sadiq
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood* / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D006801:Humans; D007577:JC Virus / Q000378:metabolism*; D008137:Longitudinal Studies; D009103:Multiple Sclerosis / Q000097:blood / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D000069442:Natalizumab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies; D015415:Biomarkers; D000069442:Natalizumab
keywords: Cerebrospinal fluid; JCV; Multiple sclerosis; Natalizumab; PML; Tysabri